A major Phase III trial reveals that the investigational drug asundexian reduces recurrent stroke risk by 26% without increasing the dangerous bleeding common in current treatments.
Most Recent Articles
Identifying Active Disease via Epigenetic Gene Signatures in Osteosarcoma Patients
Blood test identifies a unique 136-gene signature in osteosarcoma patients, providing a promising less-invasive way to monitor bone cancer recurrence and metastatic spread.
Clinical Outcomes of Truncated Antimicrobial Therapy for Community-Acquired Pneumonia
New research shows that for stable pneumonia patients, a three-day antibiotic course is just as safe and effective as traditional five-day treatments, supporting better antimicrobial stewardship.
Effectiveness of Standardized Palliative Checklists in Integrated Hepatology Practice
A major clinical trial involving 935 patients proves that hepatologists can successfully deliver high-quality palliative care, offering a scalable solution to the nationwide specialist shortage.
Differentiating Loneliness from Social Isolation in Cardiovascular Health Outcomes
New research involving 463,000 participants reveals that loneliness increases the risk of degenerative heart valve disease by up to 23%, identifying emotional well-being as a critical cardiovascular risk factor.